Free Trial
→ Do this Before Elon’s Reveal on January 22nd (From Brownstone Research) (Ad)

Cingulate Q1 2024 Earnings Report

Cingulate logo
$4.82 +0.06 (+1.26%)
As of 04:00 PM Eastern
Earnings HistoryForecast

Cingulate EPS Results

Actual EPS
-$0.60
Consensus EPS
-$2.20
Beat/Miss
Beat by +$1.60
One Year Ago EPS
N/A

Cingulate Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cingulate Announcement Details

Quarter
Q1 2024
Date
5/8/2024
Time
N/A

Conference Call Resources

Cingulate Earnings Headlines

Cingulate (NASDAQ:CING) Upgraded at Roth Capital
January 13, 2025 | americanbankingnews.com
Cingulate (NASDAQ:CING) Now Covered by Roth Mkm
January 12, 2025 | americanbankingnews.com
A deadly mistake in my prediction…
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
January 21, 2025 | Porter & Company (Ad)
Roth MKM Initiates Coverage of Cingulate (CING) with Buy Recommendation
January 10, 2025 | msn.com
Cingulate Inc’s Promising Market Positioning and Accelerated Path to Market Entry for CTx-1301
January 8, 2025 | markets.businessinsider.com
Cingulate Inc Completes Key FDA Study for ADHD Drug
January 7, 2025 | markets.businessinsider.com
See More Cingulate Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cingulate? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cingulate and other key companies, straight to your email.

About Cingulate

Cingulate (NASDAQ:CING), a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

View Cingulate Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles